{"id":19543,"date":"2022-03-12T17:57:24","date_gmt":"2022-03-12T17:57:24","guid":{"rendered":"https:\/\/zeepedia.com\/?p=19543"},"modified":"2022-03-14T11:22:15","modified_gmt":"2022-03-14T11:22:15","slug":"ogivri","status":"publish","type":"post","link":"https:\/\/zeepedia.com\/medical\/medicines\/ogivri\/","title":{"rendered":"Ogivri &#8211; Trastuzumab uses, dose and side effects"},"content":{"rendered":"\n<p>150 mg and 420 mg powder for concentrate for solution for infusion&nbsp;trastuzumab<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What Ogivri is and what it is used for<\/h2>\n\n\n\n<p>Ogivri contains the active substance <a href=\"https:\/\/zeepedia.com\/medical\/medicines\/trazimera\/\">trastuzumab<\/a>, which is a monoclonal\u00a0antibody\u00a0.\u00a0Monoclonal\u00a0antibodies\u00a0are attached to specific\u00a0proteins\u00a0or\u00a0antigens\u00a0.\u00a0Trastuzumab is designed to bind selectively to an\u00a0antigen\u00a0called\u00a0human\u00a0epidermal\u00a0growth factor receptor 2 (\u00a0HER2\u00a0).\u00a0HER2\u00a0is found in large amounts on the surface of certain cancer cells (\u00a0HER2\u00a0-positive cancer) and then stimulates cell growth.\u00a0When Ogivri binds to\u00a0HER2, the growth of the cancer cells is stopped and it leads to their death.<\/p>\n\n\n\n<p>Your doctor may prescribe Ogivri for the treatment of breast and gastric cancer then:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>You have early breast cancer with high levels of the HER2 protein.<\/li><li>You have metastatic breast cancer (breast cancer that has spread outside the original&nbsp;tumor&nbsp;) with high levels of&nbsp;HER2&nbsp;.&nbsp;Ogivri can be prescribed in combination with the&nbsp;cytotoxic&nbsp;drugs paclitaxel or docetaxel as first-line treatment for metastatic breast cancer, or it can be prescribed as the only treatment for conditions where other treatments have not shown effect.&nbsp;It is also used in combination with medicines called aromatase inhibitors for the treatment of patients with high levels of&nbsp;HER2&nbsp;and hormone receptor positive metastatic (spread) breast cancer (cancer that is sensitive to the presence of female sex hormone).<\/li><li>You have metastatic gastric cancer with high levels of HER2, as it is used in combination with capecitabine or 5-fluorouracil and cisplatin.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">What you need to know before you get Ogivri\u00a0<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Do not use Ogivri:<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>if you are allergic to trastuzumab, murine (mouse)&nbsp;protein&nbsp;, or any of the other ingredients of this medicine (listed in section 6).<\/li><li>if you have severe breathing problems at rest due to your cancer or if you need oxygen therapy.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Warnings and cautions<\/h2>\n\n\n\n<p>Your doctor will closely monitor your treatment.<\/p>\n\n\n\n<p><strong>Control of the heart<\/strong><\/p>\n\n\n\n<p>Treatment with Ogivri alone or with a taxane can affect the heart, especially if you have previously been treated with an&nbsp;anthracycline&nbsp;(taxanes and&nbsp;anthracyclines&nbsp;are two other types of medicines used to treat cancer).&nbsp;The effects can be moderate to severe and some patients have died.&nbsp;Your heart function will therefore be checked before and during treatment (every three months) and after (up to two to five years) treatment with Ogivri.&nbsp;If you develop signs of&nbsp;heart failure&nbsp;(insufficient pumping of blood from the heart), your heart function may be checked more often (every six to eight weeks).&nbsp;You may then receive treatment for&nbsp;heart failure&nbsp;or you may need to discontinue treatment with Ogivri.<\/p>\n\n\n\n<p>Talk to your doctor, pharmacist, or nurse before receiving Ogivri if:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>you have had&nbsp;heart failure&nbsp;, coronary heart disease, heart valve disease (&nbsp;wheezing&nbsp;) or high&nbsp;blood pressure&nbsp;, if you have taken or are currently taking medicines for high&nbsp;blood pressure&nbsp;.<\/li><li>you have previously received or are currently receiving a medicine called doxorubicin or epirubicin (a medicine used to treat cancer).&nbsp;These medicines (or other&nbsp;anthracyclines&nbsp;) can damage the heart muscle and increase the risk of heart problems with Ogivri.<\/li><li>you suffer from shortness of breath, especially if you are treated with a taxane at the same time.&nbsp;Ogivri can cause breathing difficulties, especially when given for the first time.&nbsp;This can be more serious if you are already short of breath.&nbsp;Patients with severe respiratory distress have in very rare cases died in connection with Ogivribe treatment.<\/li><li>you have previously received any other treatment for cancer.<\/li><\/ul>\n\n\n\n<p>If you are taking Ogivri with other medicines used to treat cancer, such as paclitaxel, docetaxel, an aromatase inhibitor, capecitabine, 5-fluorouracil, or cisplatin, you should also carefully read the package leaflets for these products.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Children and young people<\/h2>\n\n\n\n<p>Ogivri is not recommended for anyone under 18 years of age.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Other medicines and Ogivri<\/h2>\n\n\n\n<p>Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines.<\/p>\n\n\n\n<p>It can take up to 7 months for Ogivri to be removed from the body.\u00a0You should therefore tell your doctor, pharmacist, or nurse that you have been treated with Ogivri if you start any new medication within 7 months of stopping treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pregnancy and breastfeeding<\/h2>\n\n\n\n<p>If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor, pharmacist, or nurse for advice before taking this medicine.<\/p>\n\n\n\n<p>Pregnancy<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>You should use effective contraception during treatment with Ogivri and for at least 7 months after stopping treatment.<\/li><li>Your doctor will advise you on the disadvantages and benefits of taking Ogivri during pregnancy.&nbsp;In rare cases, a reduction in the amount of (fetal) fluid surrounding the growing fetus in the uterus has been observed in pregnant women treated with trastuzumab.&nbsp;This condition can be harmful to your baby in the womb and has been associated with the lungs not developing fully, resulting in fetal death.<\/li><\/ul>\n\n\n\n<p>Breast-feeding<\/p>\n\n\n\n<p>Do not breastfeed your baby during treatment with Ogivri and within 7 months after the last\u00a0dose\u00a0of Ogivri as this medicine may pass to your baby through breast milk.\u00a0Ask your doctor or pharmacist for advice before taking any medicine.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Driving and using machines<\/h2>\n\n\n\n<p>Ogivri may affect your ability to drive or use machines.\u00a0If you develop symptoms such as dizziness, drowsiness, chills, or fever during treatment, you should not drive or use machines until these symptoms have disappeared.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Ogivri contains sorbitol (E420) and sodium<\/h2>\n\n\n\n<p>Free 150 mg powder for concentrate for&nbsp;solution for&nbsp;infusion<\/p>\n\n\n\n<p>This medicine contains 115.2 mg sorbitol in each vial.<\/p>\n\n\n\n<p>Ogivri 420 mg powder for concentrate for&nbsp;solution for&nbsp;infusion<\/p>\n\n\n\n<p>This medicine contains 322.6 mg sorbitol in each\u00a0vial.<\/p>\n\n\n\n<p>Sorbitol is a source of fructose.\u00a0If you have\u00a0hereditary\u00a0fructose intolerance, a rare, inherited disease, you should not be given this medicine.\u00a0Patients with\u00a0hereditary\u00a0fructose intolerance\u00a0can not break down fructose, which can cause serious\u00a0side effects.\u00a0Talk to your doctor before using this medicine if you have\u00a0hereditary\u00a0fructose intolerance, or can no longer eat sweet food or drink without feeling sick, vomiting, or feeling uncomfortable such as bloating, stomach cramps, or diarrhea.<\/p>\n\n\n\n<p>Ogivri contains less than 1 mmol\u00a0sodium\u00a0(23 mg) per\u00a0dose, ie essentially &#8216;sodium-free&#8217;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How to get Ogivri<\/h2>\n\n\n\n<p>Before starting treatment, your doctor will determine if your&nbsp;tumor&nbsp;is&nbsp;HER2&nbsp;-positive.&nbsp;Only patients with&nbsp;HER2&nbsp;-positive cancer (large amounts of&nbsp;HER2&nbsp;) will be treated with Ogivri.&nbsp;Ogivri should only be given by a doctor or nurse.&nbsp;Your doctor will prescribe the right&nbsp;dose&nbsp;and treatment regimen for you.&nbsp;The ogivridose depends on your body weight.<\/p>\n\n\n\n<p>The first\u00a0dose\u00a0is given over 90 minutes and you will be observed by healthcare professionals while receiving it if you get any\u00a0side effects.\u00a0If the first\u00a0dose\u00a0is well tolerated, the following\u00a0dose\u00a0may be given for 30 minutes (see section 2 under \u201cWarnings and precautions\u201d).\u00a0The number of\u00a0infusions\u00a0that you receive depends on the effect of the treatment you have.\u00a0Your doctor will discuss this with you.<\/p>\n\n\n\n<p>Ogivri is given as an\u00a0infusion\u00a0into a vein (\u00a0intravenous\u00a0infusion, &#8220;drip&#8221;), this intravenous formulation is not intended for\u00a0subcutaneous\u00a0use (under the skin) and should only be given as an\u00a0intravenous\u00a0infusion.<\/p>\n\n\n\n<p>In early breast cancer, metastatic breast cancer, and metastatic gastric cancer, Ogivri is given every three weeks.\u00a0Ogivri can also be given once a week for metastatic breast cancer.<\/p>\n\n\n\n<p>To prevent medication errors, it is important to check the label of the vial to ensure that the medicine is prepared and administered is Ogivri (trastuzumab) and not any other product containing trastuzumab (eg trastuzumab emtansine or trastuzumab deruxtecan).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">If you stop using Ogivri<\/h2>\n\n\n\n<p>Do not stop using this medicine without talking to your doctor first.&nbsp;All&nbsp;doses&nbsp;should be taken at the right time each week or every three weeks (depending on your dosing interval).&nbsp;This helps the drug to work as well as possible.<\/p>\n\n\n\n<p>It can take up to 7 months before Ogivri disappears from the body.&nbsp;Therefore, your doctor may decide to continue to monitor your heart function even after treatment is over.<\/p>\n\n\n\n<p>If you have any further questions on the use of this product, ask your doctor, pharmacist, or nurse.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Possible side effects<\/h2>\n\n\n\n<p>Like all medicines, this medicine can cause\u00a0side effects, although not everybody gets them.\u00a0Some of these\u00a0side effects\u00a0can be serious and may involve hospitalization.<\/p>\n\n\n\n<p>During an\u00a0infusion\u00a0of Ogivri, chills, fever and other\u00a0flu-like symptoms\u00a0may occur.\u00a0These\u00a0side effects\u00a0are very common (may affect more than 1 in 10 people).\u00a0Other symptoms caused by\u00a0infusion\u00a0one are: nausea, vomiting, pain, increased muscle tension and tremors, headache, dizziness, difficulty breathing, high or low\u00a0blood pressure, altered heart rhythm (palpitations, heart flutter, or irregular heartbeat), swelling of the face and lips and lips.\u00a0Some of these symptoms may be severe and some patients have died (see section 2 under \u201cWarnings and precautions\u201d).<\/p>\n\n\n\n<p>These effects occur mainly in connection with the first intravenous\u00a0infusion\u00a0(drip) and during the first hours after the start of\u00a0infusion.\u00a0They are usually temporary.\u00a0You will be monitored by healthcare professionals during\u00a0infusion\u00a0one and for at least six hours after the start of the first\u00a0infusion\u00a0one and two hours after the start of the second\u00a0infusion.\u00a0If you develop symptoms, healthcare professionals will slow down or discontinue the\u00a0infusion\u00a0and they may give you treatment to counteract the\u00a0side effects.\u00a0After improvement of the symptoms, the\u00a0infusion\u00a0can be continued.<\/p>\n\n\n\n<p>Occasionally, symptoms may occur later than six hours after the start of the\u00a0infusion.\u00a0If this happens to you, contact your doctor immediately.\u00a0Sometimes the symptoms can improve and later worsen.<\/p>\n\n\n\n<p><strong>Serious&nbsp;side effects&nbsp;are<\/strong><\/p>\n\n\n\n<p>Other&nbsp;side effects&nbsp;may occur at any time during treatment with Ogivri and are not associated with the actual&nbsp;infusion&nbsp;of Ogivri.&nbsp;<strong>Tell a doctor or nurse immediately if you notice any of the following&nbsp;side&nbsp;effects&nbsp;<\/strong><strong>:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Heart problems can sometimes occur during treatment and sometimes after treatment has stopped and can be serious.&nbsp;They include weakening of the heart muscle that can possibly lead to&nbsp;heart failure&nbsp;,&nbsp;inflammation&nbsp;around the heart and altered heart rhythm.&nbsp;This can lead to symptoms such as shortness of breath (including shortness of breath during the night), cough, fluid retention (swelling) in the legs or arms, palpitations (heart flutter or irregular heartbeat) (see section 2. Checking the heart).<\/li><\/ul>\n\n\n\n<p>Your doctor will check your heart regularly during and after treatment, but you should tell your doctor immediately if you experience any of the above symptoms.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Tumor light syndrome (group of metabolic complications that occur after cancer treatment and are characterized by high levels of&nbsp;potassium&nbsp;and&nbsp;phosphate&nbsp;in the blood and low levels of&nbsp;calcium&nbsp;in the blood).&nbsp;Symptoms may include kidney problems (weakness, shortness of breath, fatigue and confusion), heart problems (heart flutter with a faster or slower heartbeat), cramps, vomiting or diarrhea and tingling in the mouth, hands or feet.<\/li><\/ul>\n\n\n\n<p>If you experience any of the above symptoms after stopping treatment with Ogivri, talk to your doctor and tell your doctor that you have previously been treated with Ogivri.<\/p>\n\n\n\n<p><strong>Very&nbsp;<\/strong><strong>&nbsp;common side effects:&nbsp;<\/strong>&nbsp;may affect more than 1 user in 10<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>infection&nbsp;is<\/li><li>diarrhea<\/li><li>constipation<\/li><li>heartburn (&nbsp;dyspepsia&nbsp;)<\/li><li>fatigue<\/li><li>rash<\/li><li>chest pain<\/li><li>abdominal pain<\/li><li>joint pain<\/li><li>low levels of red blood cells and white blood cells (which help fight&nbsp;infection&nbsp;) sometimes with fever<\/li><li>muscle pain<\/li><li>conjunctivitis (watery eyes with itching, and crusts on the eyelids)<\/li><li>watery eyes<\/li><li>nosebleeds<\/li><li>rinnsnuva<\/li><li>hair loss<\/li><li>tremors<\/li><li>hot flashes<\/li><li>dizziness<\/li><li>nail changes<\/li><li>weight loss<\/li><li>loss of appetite<\/li><li>insomnia&nbsp;_&nbsp;_<\/li><li>taste changes<\/li><li>decreased platelet count<\/li><li>bruises<\/li><li>numbness or tingling in the fingers and toes, which can sometimes spread to the rest of the arm or leg<\/li><li>redness&nbsp;, swelling or sores in the mouth and \/ or throat<\/li><li>pain, swelling, redness or tingling in the hands and \/ or feet<\/li><li>shortness of breath<\/li><li>headache<\/li><li>cough<\/li><li>vomiting<\/li><li>nausea<\/li><\/ul>\n\n\n\n<p><strong>Common&nbsp;<\/strong><strong>&nbsp;side effects:&nbsp;<\/strong>&nbsp;may affect up to 1 in 10 people<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>allergic reactions<\/li><li>dry mouth and skin<\/li><li>throat infection<\/li><li>dry eyes<\/li><li>infection&nbsp;you in the bladder and on the skin<\/li><li>sweating<\/li><li>feeling of weakness and not feeling well<\/li><li>inflammation of the chest<\/li><li>concern<\/li><li>inflammation of the liver<\/li><li>Depression<\/li><li>renal impact<\/li><li>increased muscle tone or tension (hypertension)<\/li><li>asthma<\/li><li>lung infection<\/li><li>pain in arms and \/ or legs<\/li><li>lung impact<\/li><li>itchy skin rash<\/li><li>back pain<\/li><li>drowsiness (&nbsp;somnolence&nbsp;)<\/li><li>neck pain<\/li><li>hemorrhoids (swelling of the blood vessels around the rectum)<\/li><li>skeletal pain<\/li><li>itching<\/li><li>acne<\/li><li>leg cramps<\/li><\/ul>\n\n\n\n<p><strong>Uncommon&nbsp;<\/strong><strong>&nbsp;side effects:&nbsp;<\/strong>&nbsp;may affect up to 1 in 100 people<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>deafness<\/li><li>lumpy rash<\/li><li>hissing \/ wheezing breathing<\/li><li>inflammation&nbsp;or scarring of the lungs<\/li><\/ul>\n\n\n\n<p><strong>Rare&nbsp;<\/strong><strong>&nbsp;side effects:&nbsp;<\/strong>&nbsp;may affect up to 1 in 1,000 people<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>jaundice (yellow skin and whites of the eyes)<\/li><li>anaphylactic reactions (severe rapid&nbsp;allergic reaction&nbsp;with symptoms such as rash, itchy skin, difficulty breathing or feeling dizzy or fainting)<\/li><\/ul>\n\n\n\n<p><strong>Other&nbsp;<\/strong><strong>&nbsp;side effects that have been reported:<\/strong>&nbsp;occur in an unknown number of users<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>abnormal or impaired blood coagulation<\/li><li>high potassium levels<\/li><li>swelling or bleeding behind the eyes<\/li><li>shock (dangerous drop in blood pressure that causes symptoms such as rapid, shallow breathing, cold sweats, rapid and weak heart rate, dizziness, weakness and fainting)<\/li><li>abnormal heart rhythm<\/li><li>respiratory distress<\/li><li>breathing problems<\/li><li>acute accumulation of fluid in the lungs<\/li><li>acutely narrower airways<\/li><li>abnormally low oxygen content in the blood<\/li><li>difficulty breathing when lying upright<\/li><li>liver damage<\/li><li>swelling of the face, lips and neck<\/li><li>kidney failure<\/li><li>abnormally little amniotic fluid around the fetus in the womb<\/li><li>underdeveloped lungs of the fetus in utero<\/li><li>abnormal development of the kidneys of the fetus in the womb<\/li><\/ul>\n\n\n\n<p>Some of the\u00a0side effects\u00a0you are experiencing may be due to your underlying breast cancer disease.\u00a0If you are being treated with Ogivri together with cytotoxic drugs,\u00a0some of the\u00a0side effects\u00a0may also be due to the\u00a0cytotoxic drugs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How to store Ogivri<\/h2>\n\n\n\n<p>Keep this medicine out of the sight and reach of children.<\/p>\n\n\n\n<p>Do not use this medicine after the expiry date which is stated on the outer carton and vial label after EXP.&nbsp;The expiration date is the last day of the specified month.<\/p>\n\n\n\n<p>Store in a refrigerator (2 \u00b0 C &#8211; 8 \u00b0 C).<\/p>\n\n\n\n<p>Infusion solutions should be used immediately after dilution.\u00a0Do not use Ogivri if you notice particles or discoloration before\u00a0administration.<\/p>\n\n\n\n<p>Medicines should not be disposed of via wastewater or household waste.&nbsp;Ask your pharmacist how to dispose of medicines no longer required.&nbsp;These measures will help to protect the environment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Contents of the package and other information<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Content declaration<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>The active substance is trastuzumab.&nbsp;Each&nbsp;vial&nbsp;contains either;<ul><li>150 mg trastuzumab to be dissolved in 7.2 ml of water for injections, or<\/li><li>420 mg trastuzumab to be dissolved in 20 ml water for injections.&nbsp;<\/li><\/ul><\/li><li>The reconstituted solution contains approximately 21 mg \/ ml trastuzumab.<\/li><li>The other ingredients are L-histidine hydrochloride, L-histidine, sorbitol (E420 (see section 2 &#8220;Ogivri contains sorbitol (E420) and sodium&#8221;)), macrogol 3350,&nbsp;hydrochloric acid&nbsp;and sodium hydroxide (for&nbsp;pH&nbsp;adjustment).<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">What the medicine looks like and contents of the pack<\/h2>\n\n\n\n<p>Ogivri is a powder for concentrate for\u00a0intravenous\u00a0infusion, a solution provided in a rubber stopper\u00a0vial\u00a0containing either 150 mg or 420 mg of trastuzumab.\u00a0The powder is freeze-dried and white to slightly yellow.\u00a0Each carton contains 1\u00a0vial\u00a0of powder.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Marketing Authorisation Holder<\/h2>\n\n\n\n<p>Viatris Limited<\/p>\n\n\n\n<p>Damastown Industrial Park<\/p>\n\n\n\n<p>Mulhuddart<\/p>\n\n\n\n<p>Dublin 15<\/p>\n\n\n\n<p>DUBLIN<\/p>\n\n\n\n<p>Ireland<\/p>\n\n\n\n<p><strong>Manufacturer<\/strong><\/p>\n\n\n\n<p>McDermott Laboratories Limited T \/ A Mylan Dublin Biologics<\/p>\n\n\n\n<p>Newenham Court<\/p>\n\n\n\n<p>Northern Cross<\/p>\n\n\n\n<p>Malahide Road<\/p>\n\n\n\n<p>Dublin 17<\/p>\n\n\n\n<p>Ireland<\/p>\n\n\n\n<p>Mylan Germany GmbH<\/p>\n\n\n\n<p>Branch release Bad Homburg vd Hoehe, Benzstrasse 1<\/p>\n\n\n\n<p>Bad Homburg vd Hoehe<\/p>\n\n\n\n<p>Hessen, 61352<\/p>\n\n\n\n<p>Germany<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ogivri contains the active substance trastuzumab, which is a monoclonal antibody . Monoclonal antibodies are attached to specific proteins or antigens . Trastuzumab is designed to bind selectively to an antigen called human epidermal growth factor receptor 2 ( HER2 ). HER2 is found in large amounts on the surface of certain cancer cells ( HER2 -positive cancer) and then stimulates cell growth. When Ogivri binds to HER2 , the growth of the cancer cells is stopped and it leads to their death.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2200,18526],"tags":[19730,13803,19726,19729,13800,13804,19727,13801,19728,13802],"class_list":["post-19543","post","type-post","status-publish","format-standard","hentry","category-medicines","category-o","tag-benefits-of-fogivri","tag-benefits-of-trastuzumab","tag-ogivri","tag-ogivri-side-effects","tag-trastuzumab","tag-trastuzumab-side-effects","tag-what-is-ogivri","tag-what-is-trastuzumab","tag-what-ogivri-is-used-for","tag-what-trastuzumab-is-used-for"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/19543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=19543"}],"version-history":[{"count":4,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/19543\/revisions"}],"predecessor-version":[{"id":19595,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/19543\/revisions\/19595"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=19543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=19543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=19543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}